Oncology Program Articles & Analysis
30 news found
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a new cohort of compounds to be tested in Q4 2025. ...
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, ...
ByBayer AG
The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. ...
ByBayer AG
“We are pleased that our trusted and long-standing collaborator Novartis will continue to drive this program forward. Novartis has strong medicinal chemistry, oncology development and translational research capabilities to realize the full potential of this novel cancer target,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. ...
(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference ...
Under the agreement, Chimeric gains exclusive global rights to the CORE-NK platform for oncology, where Chimeric and CWRU are currently advancing multiple product candidates in Dr Wald’s laboratory under the recently announced Sponsored Research Agreement. ...
“I am impressed by the pipeline’s breadth of novel, first-in-class programs in oncology and immunology. These programs are nearly all targeting proteins the industry has previously viewed as undruggable, and indicate the potential to deliver enormous value to patients if successful. ...
ByBayer AG
Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds Tavros Therapeutics, Inc., a ...
ByBayer AG
iBio closed on acquiring several assets from the San Diego-based biotech RubrYc Therapeutics, snapping up several oncology programs. The cost includes a $1 million upfront payment as well as the ability of RubrYc’s investors to receive up to $5 million in milestones over the next several years. ...
Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC) Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which ...
ByBayer AG
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth ...
"Her addition to our team comes at an exciting inflection point for our growth, as we clearly see the potential to advance multiple programs into the clinic starting next year." "I am very excited to join Vividion to continue to advance innovation in an entrepreneurial environment focused on patient benefits and outcomes," said Dr. ...
ByBayer AG
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell therapy designed for the ...
Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center. He served as the past President of American Society of Clinical Oncology (ASCO) from 2015 to 2018 and is a world-recognized thought leader in the field of breast cancer. ...
Rajangam will be broadly responsible for leading the development and regulatory strategy to rapidly advance Senti Bio's off-the-shelf CAR-NK cell oncology programs into and through clinical development. Dr. Rajangam joins Senti Bio from Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for ...
Sallés joins the Kallyope senior leadership team as the company advances its pioneering drug discovery platform, clinical trials, and pipeline of multiple programs modulating gut-brain axis signaling across a broad range of therapeutic areas. ...
Genentech will assume responsibility for further clinical development and commercialization of Lineage’s OpRegen program, which currently is being evaluated in a Phase 1/2a open-label, dose escalation clinical safety and efficacy study in patients with advanced dry AMD with GA. ...
Hans van der Vliet, M.D., Ph.D., professor, medical oncology, Amsterdam UMC and chief scientific officer, LAVA Therapeutics Prof. Daniel Olive, M.D., Ph.D., head of the immunity and cancer lab, Cancer Research Center of Marseille; professor, immunology and director, oncology research programs, Aix Marseille University; scientific founder and ...
“We expect this financing to enable us to reach key value inflection points for our lead programs,” said Bill Enright, Chief Executive Officer of Vaccitech. “We now look forward to advancing key programs towards generating proof-of-concept data in indications with significant need of effective new treatments.” The proceeds from the ...
The company recently unveiled its growing portfolio of emerging joint venture companies, with drug development programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. ...